Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis.

Fired Hutchinson Cancer Research Center, Seattle, WA 98109-1023, USA.
Cancer (Impact Factor: 4.9). 05/2011; 117(10):2024-34. DOI: 10.1002/cncr.25770
Source: PubMed

ABSTRACT Estrogen receptor (ER) remains one of the most important biomarkers for breast cancer subtyping and prognosis, and comparative genome hybridization has greatly contributed to the understanding of global genetic imbalance. The authors used single-nucleotide polymorphism (SNP) arrays to compare overall copy number aberrations (CNAs) as well as loss of heterozygosity (LOH) of the entire human genome in ER-positive and ER-negative breast carcinomas.
DNA was extracted from frozen tumor sections of 21 breast carcinoma specimens and analyzed with a proprietary 50K XbaI SNP array. Copy number and LOH probability values were derived for each sample. Data were analyzed using bioinformatics and computational software, and permutation tests were used to estimate the significance of these values.
There was a global increase in CNAs and LOH in ER-negative relative to ER-positive cancers. Gain of the long arm of chromosome 1 (1q) and 8q were the most obvious changes common in both subtypes: An increase in the chromosome 1 short arm (1p)/1q ratio was observed in ER-negative samples, and an increased 16p/16q ratio was observed in ER-positive samples. Significant CNAs (adjusted P<.05) in ER-negative relative to ER-positive tumors included 5q deletion, loss of 15q, and gain of 2p and 21q. Copy-neutral LOH (cnLOH) common to both ER-positive and ER-negative samples included 9p21, the p16 tumor suppressor locus, and 4q13, the RCHY1 (ring finger and CHY zinc finger domain-containing 1) oncogene locus. Of particular interest was an enrichment of 17q LOH among the ER-negative tumors, potentially suggesting breast cancer 1 gene (BRCA1) mutations.
SNP array detected both genetic imbalances and cnLOH and was capable of discriminating ER-negative breast cancer from ER-positive breast cancer.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Clustering is crucial for gene expression data analysis. As an unsupervised exploratory procedure its results can help researchers to gain insights and formulate new hypothesis about biological data from microarrays. Given different settings of microarray experiments, clustering proves itself as a versatile exploratory tool. It can help to unveil new cancer subtypes or to identify groups of genes that respond similarly to a specific experimental condition. In order to obtain useful clustering results, however, different parameters of the clustering procedure must be properly tuned. Besides the selection of the clustering method itself, determining which distance is going to be employed between data objects is probably one of the most difficult decisions. We analyze how different distances and clustering methods interact regarding their ability to cluster gene expression, i.e., microarray data. We study 15 distances along with four common clustering methods from the literature on a total of 52 gene expression microarray datasets. Distances are evaluated on a number of different scenarios including clustering of cancer tissues and genes from short time-series expression data, the two main clustering applications in gene expression. Our results support that the selection of an appropriate distance depends on the scenario in hand. Moreover, in each scenario, given the very same clustering method, significant differences in quality may arise from the selection of distinct distance measures. In fact, the selection of an appropriate distance measure can make the difference between meaningful and poor clustering outcomes, even for a suitable clustering method.
    BMC Bioinformatics 01/2014; 15 Suppl 2:S2. · 2.67 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Genomic aberrations are common in cancers and the long arm of chromosome 1 is known for its frequent amplifications in breast cancer. However, the key candidate genes of 1q, and their contribution in breast cancer pathogenesis remain unexplored. We have analyzed the gene expression profiles of 1635 breast tumor samples using meta-analysis based approach and identified clinically significant candidates from chromosome 1q. Seven candidate genes including exonuclease 1 (EXO1) are consistently over expressed in breast tumors, specifically in high grade and aggressive breast tumors with poor clinical outcome. We derived a EXO1 co-expression module from the mRNA profiles of breast tumors which comprises 1q candidate genes and their co-expressed genes. By integrative functional genomics investigation, we identified the involvement of EGFR, RAS, PI3K / AKT, MYC, E2F signaling in the regulation of these selected 1q genes in breast tumors and breast cancer cell lines. Expression of EXO1 module was found as indicative of elevated cell proliferation, genomic instability, activated RAS/AKT/MYC/E2F1 signaling pathways and loss of p53 activity in breast tumors. mRNA-drug connectivity analysis indicates inhibition of RAS/PI3K as a possible targeted therapeutic approach for the patients with activated EXO1 module in breast tumors. Thus, we identified seven 1q candidate genes strongly associated with the poor survival of breast cancer patients and identified the possibility of targeting them with EGFR/RAS/PI3K inhibitors.
    PLoS ONE 10/2013; 8(10):e77553. · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent technological advances have made it possible to detect circulating tumor cells (CTCs) as a prognostic marker in operable breast cancer patients. Whether the presence of CTCs in cancer patients correlates with molecular alterations in the primary tumor has not been widely explored. We identified 14 primary breast cancer specimens with known CTC status, in order to evaluate the presence of differential genetic aberrations by using SNP array assay. There was a global increase of altered genome, CNA, and copy-neutral loss of heterozygosity (cn-LOH) observed in the CTC-positive (CTC(+)) versus CTC-negative (CTC(-)) cases. As the preliminary results showed a higher proportion of copy number alteration (CNA) at 8q24 (MYC loci) and the available evidence supporting the role of MYC in the processes cancer metastases is conflicting, MYC status was determined in tissue microarray sections in a larger series of patients (n = 49) with known CTC status using FISH. MYC was altered in 62 % (16/26) CTC(+) patients and in 43 % (6/14) CTC(-) patients (p = 0.25). Based on the observation in our study, future studies involving a larger number of patients should be performed in order to definitively define if this correlation exists.
    Tumor Biology 10/2014; · 2.84 Impact Factor